2024
Improving access to first‐line treatment for pediatric obesity: Lessons from the dissemination of SmartMoves
Finn E, Keller C, Gowey M, Savoye M, Samuels S, Fleisch A, Rogers V, Grey M, Damschroder L, Beck A, Sharifi M. Improving access to first‐line treatment for pediatric obesity: Lessons from the dissemination of SmartMoves. Obesity 2024, 32: 1745-1756. PMID: 39192771, DOI: 10.1002/oby.24107.Peer-Reviewed Original ResearchConceptsConstant comparative methodInterviewed key informantsHealth behaviorsObesity programsSufficient staffingInsufficient staffingPediatric obesityFunding insecurityLifestyle treatmentImprove accessOrganizational prioritiesProgram componentsProgram fitPromote fidelityKey informantsUS sitesIncreased prevalenceAdequate fundingSurvey findingsStaffingParticipantsInterviewsCOVID-19 pandemicDominant barriersObesityOverview of the Treatment of Pediatric Obesity and the 2023 Clinical Practice Guidelines
Hu P, Samuels S, Sharifi M. Overview of the Treatment of Pediatric Obesity and the 2023 Clinical Practice Guidelines. Pediatric Clinics Of North America 2024, 71: 919-926. PMID: 39343501, DOI: 10.1016/j.pcl.2024.06.005.Peer-Reviewed Original ResearchReal‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
Samuels S, Chajecki A, Hu P, Kayser M, Weyman K, Pan B, Brown E, Van Name M, Wolf R. Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c. Diabetes Obesity And Metabolism 2024, 26: 1305-1313. PMID: 38229444, DOI: 10.1111/dom.15430.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RAFollow-upType 2 diabetesReceptor agonistsGLP-1RAsDiverse cohort of youthEffects of glucagon-like peptide-1 receptor agonistsBody mass index z-scoreMedian follow-upMulticentre retrospective studyReduced insulin doseGLP-1RA treatmentPatients prescribed insulinFollow-up visitAssociated with short-term improvementsPaediatric diabetes centresManagement of type 2 diabetesManagement of T2DMetformin regimenBMI-zMedian HbA1cRetrospective studyDosing frequency
2023
1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis
SAMUELS S, CHAJECKI A, HU P, KAYSER M, WEYMAN K, PAN B, BROWN E, VAN NAME M, WOLF R. 1100-P: Real-World Use of GLP-1 Agonists in Youth with Type 2 Diabetes Is Associated with Improvements in Hemoglobin A1c—A Multicenter Analysis. Diabetes 2023, 72 DOI: 10.2337/db23-1100-p.Peer-Reviewed Original ResearchGlucagon-like-peptide-1 agonistsFollow-upAmerican Diabetes AssociationType 2 diabetesManagement of T2DDiverse cohort of youthReduced doses of insulinMonths of follow-upMulticenter retrospective analysisGlucagon-like-peptide-1High risk of diabetic complicationsGLP-1 agonistsRisk of diabetic complicationsDoses of insulinPediatric diabetes centersBaseline to follow-upAssociated with improvementsMetformin usePharmacological optionsReduced dosePediatric populationPrandial insulinPrescribed metforminRetrospective analysisNational Institutes of HealthComparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity
Galuppo B, Umano G, Li Z, Van Name M, Samuels S, Kien C, Cline G, Wagner D, Barbieri E, Tricò D, Santoro N. Comparison of Metabolic Response to Colonic Fermentation in Lean Youth vs Youth With Obesity. JAMA Network Open 2023, 6: e2312530. PMID: 37159195, PMCID: PMC10170343, DOI: 10.1001/jamanetworkopen.2023.12530.Peer-Reviewed Original ResearchConceptsInsulin sensitivity indexCross-sectional studyFree fatty acidsColonic fermentationActive glucagon-like peptide-1Plasma free fatty acidsGlucagon-like peptide-1Indigestible dietary carbohydratesReduction of ghrelinActive GLP-1Health care burdenBody mass indexMetabolic responseInsulin-resistant groupLean youthObese insulinOIS groupPYY responseAnorexigenic responsePediatric obesityMass indexTyrosine tyrosineInsulin resistanceIntravenous infusionHormone secretionRising NAFLD and metabolic severity during the Sars‐CoV‐2 pandemic among children with obesity in the United States
Slusher A, Hu P, Samuels S, Tokoglu F, Lat J, Li Z, Alguard M, Strober J, Vatner D, Shabanova V, Caprio S. Rising NAFLD and metabolic severity during the Sars‐CoV‐2 pandemic among children with obesity in the United States. Obesity 2023, 31: 1383-1391. PMID: 36694381, PMCID: PMC10186584, DOI: 10.1002/oby.23728.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseOral glucose tolerance testGlucose tolerance testProton density fat fractionLiver diseaseSars-Cov-2 pandemicTolerance testSeverity of NAFLDMagnetic resonance imaging-derived proton density fat fractionFrequency-matched control groupIntrahepatic fat contentCommon liver diseaseFatty liver diseasePediatric obesity clinicVisceral adipose tissueGlobal pandemicNAFLD prevalenceObesity clinicMetabolic severityInsulin secretionAdipose tissueControl groupObesityPatient careHealth differences
2022
Real‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity
Samuels S, Hu P, Maciejewski K, Li F, Dziura J, Savoye M, Sharifi M. Real‐world effectiveness of the Bright Bodies healthy lifestyle intervention for childhood obesity. Obesity 2022, 31: 203-213. PMID: 36502287, PMCID: PMC9780185, DOI: 10.1002/oby.23627.Peer-Reviewed Original ResearchConceptsPediatric weight management interventionsHealthy lifestyle interventionReal-world effectivenessWeight management interventionsLifestyle interventionChildhood obesityClinical effectivenessFemale sexInsurance categoriesBMIp95Mixed-effects modelsGreater reductionBMIBright bodiesInterventionSexParticipantsManagement interventionsObesityReal-world adaptationYearsTrialsMechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach
Tricò D, McCollum S, Samuels S, Santoro N, Galderisi A, Groop L, Caprio S, Shabanova V. Mechanistic Insights Into the Heterogeneity of Glucose Response Classes in Youths With Obesity: A Latent Class Trajectory Approach. Diabetes Care 2022, 45: 1841-1851. PMID: 35766976, PMCID: PMC9346992, DOI: 10.2337/dc22-0110.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testΒ-cell functionΒ-cell glucose sensitivityInsulin sensitivityGenetic risk profileMultiple oral glucose tolerance testsDifferent genetic risk profilesRisk profileMin oral glucose tolerance testLatent class trajectory analysisGlucose tolerance testImpaired insulin sensitivityPlasma glucose responseGlucose sensitivityClass 3Model-predicted probabilityClass 1Tolerance testProgressive impairmentMultiethnic cohortGlucose responseLongitudinal changesObesityTransient reductionInsulin kinetics342-OR: Low Incretin Effect Is Associated with Longitudinal Decline of Beta-Cell Function and Insulin Sensitivity in Obese Youth
GALDERISI A, LAT J, SAMUELS S, PIERPONT B, VAN NAME M, SANTORO N, CAPRIO S. 342-OR: Low Incretin Effect Is Associated with Longitudinal Decline of Beta-Cell Function and Insulin Sensitivity in Obese Youth. Diabetes 2022, 71 DOI: 10.2337/db22-342-or.Peer-Reviewed Original ResearchBeta-cell functionIncretin effectInsulin sensitivityInsulin secretionCell functionFirst-phase insulin secretionIsoglycemic intravenous glucose infusionLongitudinal declineReduced β-cell functionEarly insulin secretionLower insulin sensitivityIntravenous glucose infusionΒ-cell functionOral minimal modelIncretin groupsObese youthGlucose infusionRelative increaseNational InstituteTertileLongitudinal trajectoriesObesitySecretionGlucoseGroup
2021
The Yale Bright Bodies Lifestyle Intervention Program: An Intensive Lifestyle Intervention for Obese Children and Adolescents With and Without T2D
Savoye M, Rose P, Samuels S, Tamborlane W, Caprio S, Van Name M. The Yale Bright Bodies Lifestyle Intervention Program: An Intensive Lifestyle Intervention for Obese Children and Adolescents With and Without T2D. Contemporary Endocrinology 2021, 203-216. DOI: 10.1007/978-3-030-64133-7_19.ChaptersLifestyle intervention programLifestyle interventionObese childrenIntensive lifestyle intervention programPediatric lifestyle interventionCornerstone of treatmentIntensive lifestyle interventionPrevalence of obesityType 2 diabetesIntervention programsOverproduction of insulinInsulin sensitivityClinical studiesBody weightCaregiver supportT2DChildrenInterventionPrevalenceAdolescentsGlycemiaObesityDiabetesT2D.DietitiansCurrent Treatment of Pediatric Type 2 Diabetes
Samuels S, Van Name M, Guandalini C, Tamborlane W, Caprio S. Current Treatment of Pediatric Type 2 Diabetes. Contemporary Endocrinology 2021, 191-202. DOI: 10.1007/978-3-030-64133-7_18.Chapters
2020
Fatty liver, irrespective of ethnicity, is associated with reduced insulin clearance and insulin resistance in obese youths
Trico D, Galderisi A, Galuppo B, Pierpont B, Samuels S, Santoro N, Caprio S. Fatty liver, irrespective of ethnicity, is associated with reduced insulin clearance and insulin resistance in obese youths. Endocrine Abstracts 2020 DOI: 10.1530/endoabs.70.aep256.Peer-Reviewed Original Research